PRA Health Sciences Inc. is facing an antitrust lawsuit from shareholders of an acquired company, with claims that PRA’s post-merger conduct prevented a further payout from the deal.
In 2017, PRA, one of the largest clinical research organizations, acquired Parallel 6, a developer of software to manage clinical trials and enrollment.
Once the acquisition was completed, PRA allegedly withheld sales of Parallel 6 products to PRA’s competitors, the May 28 complaint alleged. The move prevented Parallel 6 from meeting a sales growth target that was tied to a $10 million “contingent consideration” to be paid to its shareholders, according to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.